The rapid growing of genome editing technology leads to an optimistic expectation for the treatment of many incurable diseases. The core of genome editing relies on DNA-repairing processes which occur independently in each cell, thus generating a mix of genetic variation cells. Here, we describe the protocol of using mesenchymal stem cells as a platform to generate high purity of ZFN-edited patients' cell clones which may be useful in conjunction with therapeutic cell conversion and reprograming.
Keywords: Genome editing; Homologous recombination; Mesenchymal stem cells; Zinc-finger nuclease (ZFN).